Gene Location [1]
Cell cycle control
Variant Type

TP53 Loss is present in 0.70% of AACR GENIE cases, with prostate adenocarcinoma, breast invasive ductal carcinoma, undifferentiated pleomorphic sarcoma, uterine corpus leiomyosarcoma, and leiomyosarcoma having the greatest prevalence [4].

Top Disease Cases with TP53 Loss

Significance of TP53 Loss in Diseases

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Acute Lymphoblastic Leukemia +

Chronic Myelomonocytic Leukemia +

Secondary Acute Myeloid Leukemia +

Multiple Myeloma +

Prostate Carcinoma +

Non-Hodgkin Lymphoma +

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

Chronic Lymphocytic Leukemia +

Hodgkin Lymphoma +

Breast Carcinoma +

Colorectal Carcinoma +

Chronic Myeloid Leukemia +

T-Cell Acute Lymphoblastic Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Mantle Cell Lymphoma +

B-Cell Non-Hodgkin Lymphoma +

Lymphoma +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Head And Neck Squamous Cell Carcinoma +

Urothelial Carcinoma +

Ovarian Carcinoma +

Pancreatic Carcinoma +

B-Cell Acute Lymphoblastic Leukemia +

Sarcoma +

Diffuse Large B-Cell Lymphoma +

Small Cell Lung Carcinoma +

T-Cell Non-Hodgkin Lymphoma +

Mature T-Cell And NK-Cell Neoplasm +

Uterine Carcinosarcoma +

Glioblastoma +

Anaplastic Astrocytoma +

Cancer +

Endometrial Serous Adenocarcinoma +

Indolent Non-Hodgkin Lymphoma +

Bladder Carcinoma +

Head And Neck Carcinoma +

Melanoma +

High Grade Ovarian Serous Adenocarcinoma +

Colorectal Adenocarcinoma +

Follicular Lymphoma +

Squamous Cell Lung Carcinoma +

Acute Leukemia +

Leukemia +

Acute Bilineal Leukemia +

Acute Biphenotypic Leukemia +

Acute Myeloid Leukemia With Myelodysplasia-Related Changes +

Breast Lobular Carcinoma In Situ +

Clear Cell Renal Cell Carcinoma +

Double-Hit Lymphoma +

Esophageal Squamous Cell Carcinoma +

Hereditary Breast And Ovarian Cancer Syndrome +

Histiocytic And Dendritic Cell Neoplasm +

Mixed Phenotype Acute Leukemia +

Myelodysplastic Syndrome With Excess Blasts-2 +

Myelodysplastic/Myeloproliferative Neoplasm +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Myelofibrosis +

Myeloproliferative Neoplasm +

Peripheral T-Cell Lymphoma +

Polycythemia Vera +

Primary Myelofibrosis +

Prolymphocytic Leukemia +

Refractory Anemia +

Refractory Anemia With Excess Blasts +

Secondary Myelodysplastic Syndrome +

Smoldering Plasma Cell Myeloma +

Therapy-Related Myelodysplastic Syndrome +

Waldenstrom Macroglobulinemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.